HE 3235

Drug Profile

HE 3235

Alternative Names: Apoptone; HE-3235

Latest Information Update: 29 Sep 2015

Price : $50

At a glance

  • Originator Hollis-Eden Pharmaceuticals
  • Developer Harbor Therapeutics
  • Class Androstanols; Antineoplastics; Hormonal steroids; Small molecules
  • Mechanism of Action Androgen receptor antagonists; Apoptosis stimulants; Raf kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Prostate cancer

Most Recent Events

  • 29 Sep 2015 Discontinued - Phase-I/II for Prostate cancer (Hormone refractory, Late-stage disease, Treatment-experienced) in USA (PO)
  • 29 Sep 2015 Discontinued - Preclinical for Breast cancer in USA (PO)
  • 28 Feb 2011 Pharmacodynamics data from animal studies in breast cancer released by Harbor BioSciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top